Hospital
Mainehealth
Mainehealth was paid $2.62M by Medicaid between Jan 2018 and Dec 2024, across 250 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoMAINEHEALTH
DAMARISCOTTA, ME 04543
DAMARISCOTTA, ME 04543
33aNPI1912094806assigned 10/10/2006
33bProvider typeCritical Access Hospital
28Total paid$2.62M
24GClaims473,036
24DCodes billed250
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Maine
Rank by total paid#5 of 14
Median peer was paid$1.76M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HUNTER, ROBERT controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,745 | $377K | |
| 2019 | 53,175 | $401K | |
| 2020 | 53,471 | $282K | |
| 2021 | 79,463 | $322K | |
| 2022 | 80,145 | $343K | |
| 2023 | 83,236 | $462K | |
| 2024incomplete | 76,801 | $432K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 21,637 | 13,273 | $326K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 9,849 | 5,820 | $281K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.8% | 2,356 | 2,196 | $230K |
| G0378 | Hospital observation service, per hour | 4.6% | 1,083 | 910 | $120K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.2% | 13,252 | 9,674 | $111K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.2% | 8,811 | 7,488 | $109K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 1,992 | 1,865 | $105K |
| 71046 | Radiologic examination, chest; 2 views | 3.7% | 5,382 | 4,987 | $96K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.2% | 3,913 | 2,886 | $83K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 14,424 | 5,583 | $69K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 745 | 713 | $68K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.4% | 12,287 | 9,147 | $62K |
238 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 8,752 | $55K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.8% | 1,728 | $47K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.8% | 9,022 | $46K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.5% | 3,826 | $41K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.4% | 317 | $38K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.4% | 2,982 | $36K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 4,005 | $35K |
| 80053 | Comprehensive metabolic panel | 1.3% | 25,487 | $33K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.2% | 10,148 | $30K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 12,709 | $29K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,247 | $28K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 4,354 | $27K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 26,475 | $23K |
| 73564 | <1% | 1,515 | $22K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 447 | $22K |
| 71250 | <1% | 297 | $21K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,377 | $19K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 439 | $19K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,944 | $18K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 10,334 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 830 | $15K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 655 | $14K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 153 | $13K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,657 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,397 | $13K |
| 73030 | <1% | 1,265 | $11K | |
| 73502 | <1% | 773 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,151 | $10K |
| 97162 | <1% | 1,310 | $10K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,708 | $10K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,753 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,452 | $9K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 251 | $9K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,655 | $8K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 3,205 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,010 | $7K |
| 73630 | <1% | 829 | $7K | |
| 97166 | <1% | 841 | $7K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 66 | $6K |
| 96376 | <1% | 1,136 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,168 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,952 | $6K |
| 73610 | <1% | 1,069 | $5K | |
| 83880 | <1% | 1,907 | $5K | |
| 20610 | <1% | 710 | $5K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 120 | $4K |
| 84484 | <1% | 5,357 | $4K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 335 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,075 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 316 | $4K |
| 73130 | <1% | 443 | $3K | |
| 83735 | <1% | 3,491 | $3K | |
| 82607 | <1% | 1,792 | $3K | |
| 73110 | <1% | 492 | $3K | |
| 81001 | <1% | 5,280 | $3K | |
| 97803 | <1% | 1,069 | $3K | |
| 85027 | <1% | 2,960 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 7,391 | $3K |
| 82728 | <1% | 1,648 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 820 | $3K |
| 86140 | <1% | 4,412 | $3K | |
| 87077 | <1% | 2,603 | $2K | |
| 85610 | <1% | 5,289 | $2K | |
| 97161 | <1% | 498 | $2K | |
| 87186 | <1% | 2,236 | $2K | |
| 82043 | <1% | 1,189 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,744 | $2K |
| 82746 | <1% | 1,143 | $2K | |
| 84439 | <1% | 1,444 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,691 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,393 | $2K |
| 83550 | <1% | 1,471 | $2K | |
| 80061 | Lipid panel | <1% | 5,601 | $2K |
| 83540 | <1% | 1,548 | $2K | |
| 83690 | <1% | 3,652 | $2K | |
| 93971 | <1% | 44 | $2K | |
| 87070 | <1% | 3,999 | $2K | |
| 86618 | <1% | 1,842 | $2K | |
| 83605 | <1% | 1,986 | $2K | |
| 87040 | <1% | 2,019 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,442 | $1K |
| 82948 | <1% | 3,965 | $1K | |
| 92134 | <1% | 361 | $1K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 28 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,022 | $1K |
| 85652 | <1% | 1,914 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 951 | $1K |
| 87481 | <1% | 479 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 905 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 5,272 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,291 | $995.79 |
| 81003 | <1% | 2,528 | $991.18 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 114 | $957.34 |
| 92133 | <1% | 387 | $905.60 | |
| 86803 | <1% | 1,511 | $904.69 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,090 | $870.04 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,090 | $870.04 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 162 | $839.35 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 653 | $805.16 |
| 86850 | <1% | 1,142 | $779.80 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 980 | $760.93 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,370 | $743.47 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $733.13 |
| 73140 | <1% | 183 | $713.28 | |
| 93242 | <1% | 57 | $708.66 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 300 | $662.00 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 293 | $622.62 |
| 87205 | <1% | 955 | $621.20 | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 92 | $621.09 |
| 87469 | <1% | 612 | $598.49 | |
| 87468 | <1% | 612 | $597.98 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 375 | $594.17 |
| 72110 | <1% | 39 | $576.09 | |
| 96367 | <1% | 64 | $555.41 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 65 | $540.86 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 251 | $522.06 |
| 87511 | <1% | 246 | $521.63 | |
| 99220 | <1% | 78 | $504.77 | |
| 83970 | <1% | 52 | $503.24 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,681 | $493.99 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,632 | $487.71 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,883 | $477.94 |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $471.56 |
| 85379 | <1% | 875 | $460.90 | |
| 99441 | <1% | 67 | $447.70 | |
| 86900 | <1% | 1,181 | $435.44 | |
| 72100 | <1% | 30 | $435.40 | |
| 86901 | <1% | 1,188 | $431.44 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,512 | $420.39 |
| 80306 | <1% | 988 | $369.11 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 496 | $359.26 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,096 | $354.78 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 169 | $312.81 |
| 84100 | <1% | 312 | $302.34 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 76 | $259.88 |
| 92015 | Determination of refractive state | <1% | 619 | $251.35 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,375 | $230.88 |
| 90715 | <1% | 190 | $227.59 | |
| 92083 | <1% | 49 | $222.06 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 860 | $216.22 |
| 81002 | <1% | 1,261 | $207.16 | |
| 85730 | <1% | 429 | $197.28 | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,090 | $190.80 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 116 | $187.84 |
| 85018 | <1% | 1,247 | $178.56 | |
| 88142 | <1% | 801 | $175.79 | |
| 97116 | <1% | 105 | $169.78 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 291 | $151.04 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 229 | $149.51 |
| 99223 | Prolong inpt eval add15 m | <1% | 72 | $142.34 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,532 | $137.03 |
| 94727 | <1% | 22 | $127.27 | |
| 81025 | <1% | 588 | $124.77 | |
| 00811 | <1% | 18 | $123.14 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 42 | $122.20 |
| 84703 | <1% | 2,417 | $121.18 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 20 | $116.21 |
| 82570 | <1% | 70 | $112.43 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 21 | $103.49 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 44 | $103.41 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 184 | $102.34 |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 31 | $100.48 |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 29 | $91.53 |
| 99217 | <1% | 57 | $89.25 | |
| 86617 | <1% | 57 | $84.81 | |
| 82550 | <1% | 100 | $84.08 | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 34 | $75.60 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 238 | $75.17 |
| 87428 | <1% | 256 | $74.58 | |
| 17000 | <1% | 24 | $72.99 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 67 | $68.31 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,593 | $62.80 |
| 93244 | <1% | 27 | $59.80 | |
| 80305 | <1% | 3,414 | $58.67 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 64 | $58.33 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,492 | $56.34 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 16 | $56.16 |
| 84702 | <1% | 258 | $54.50 | |
| 87340 | <1% | 162 | $51.17 | |
| 84481 | <1% | 12 | $45.60 | |
| 87400 | <1% | 248 | $43.97 | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $42.81 |
| 99205 | Prolong outpt/office vis | <1% | 14 | $40.77 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 64 | $40.27 |
| 86038 | <1% | 15 | $29.15 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 56 | $25.49 |
| 36416 | <1% | 19 | $24.80 | |
| 85014 | <1% | 41 | $24.01 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 45 | $23.44 |
| 86431 | <1% | 12 | $19.68 | |
| 82803 | <1% | 36 | $19.61 | |
| 83615 | <1% | 12 | $18.42 | |
| 86364 | <1% | 13 | $15.62 | |
| 87484 | <1% | 13 | $15.12 | |
| G0008 | Administration of influenza virus vaccine | <1% | 196 | $13.67 |
| 80050 | General health panel | <1% | 33 | $8.50 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 100 | $8.31 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 106 | $8.05 |
| 85651 | <1% | 187 | $8.03 | |
| 86780 | <1% | 332 | $6.76 | |
| 82784 | <1% | 28 | $6.68 | |
| 84156 | <1% | 14 | $6.67 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 44 | $6.35 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 16 | $5.02 |
| 90686 | <1% | 181 | $4.59 | |
| 99459 | <1% | 15 | $3.42 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 232 | $2.82 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 49 | $1.08 |
| 84403 | <1% | 27 | $0.26 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 812 | $0.09 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 138 | $0.01 |
| 0011A | 0% | 1,102 | $0.00 | |
| 0001A | 0% | 192 | $0.00 | |
| 0012A | 0% | 1,171 | $0.00 | |
| 91301 | 0% | 1,329 | $0.00 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 0% | 13 | $0.00 |
| 0064A | 0% | 363 | $0.00 | |
| 0072A | 0% | 181 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 37 | $0.00 |
| 86762 | 0% | 14 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 16 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 93 | $0.00 |
| 83655 | 0% | 784 | $0.00 | |
| 00812 | 0% | 12 | $0.00 | |
| 80076 | 0% | 43 | $0.00 | |
| 91300 | 0% | 529 | $0.00 | |
| 87420 | 0% | 81 | $0.00 | |
| 85007 | 0% | 27 | $0.00 | |
| 59025 | Fetal non-stress test | 0% | 81 | $0.00 |
| 83037 | 0% | 18 | $0.00 | |
| 0034A | 0% | 12 | $0.00 | |
| 0002A | 0% | 200 | $0.00 | |
| 84550 | 0% | 19 | $0.00 | |
| 0004A | 0% | 163 | $0.00 | |
| 0071A | 0% | 180 | $0.00 | |
| 0054A | 0% | 20 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 36 | $0.00 |
| 82947 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUNTER, ROBERT (SENIOR VICE PRESIDENT - FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Mainehealth | Rockport, ME | $31.54M |
| Mainehealth | Farmington, ME | $16.71M |
| Mainehealth | Norway, ME | $10.00M |
| Mainehealth | Norway, ME | $9.84M |
| Mainehealth | Damariscotta, ME | $9.60M |
| Mainehealth | Belfast, ME | $5.33M |
| Mainehealth | Norway, ME | $5.06M |
| Mainehealth | Livermore Falls, ME | $3.15M |
| Mainehealth | Boothbay Harbor, ME | $2.90M |
| Mainehealth | Farmington, ME | $2.36M |
| University Pathologists | Houston, TX | $1.35M |
| Mainehealth | Farmington, ME | $435K |
| P R Hematology Oncology Group INC | Bayamon, PR | $69K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.